Rana KZ, Horton CM, Yuen GJ, Pivarnik PE, Mikolich DM, Fisher AE, Mydlow PK, Dudley MN; Interscience Conference on Antimicrobial Agents and Chemotherapy.
Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother. 1994 Oct 4-7; 83.
Univ. of Rhode Island, Providence, RI.
Lamivudine (3TC(TM)) is a new reverse transcriptase inhibitor active against HIV. In vitro studies have shown synergy in combination with zidovudine (ZDV) and 3TC is currently in Phase II/III clinical trials in combination with ZDV. This study was conducted to determine the effects of concomitant administration of oral 3TC on the pharmacokinetics of oral ZDV. Twelve asymptomatic HIV- infected patients with CD4 counts greater than or equal to 200/mm3 received 3TC 300mg twice daily x 48h, and then the combination 3TC 300mg + ZDV 200mg was administered on the study day. Serum and urine samples were collected over 12h and analyzed for ZDV and its glucuronide metabolite (GZDV) by fluorescence polarization immunoassay. A 2-compartment model was fit to data using extended least-squares regression, and parameters were compared using the paired t- test and signed-rank test. The parameters (mean +/- SD) for ZDV alone and in combination with 3TC are as follows: (table: see text). There were no statistically significant differences in ZDV or GZDV parameters. Although a trend for a change in ZDV CL/F was observed, oral 3TC does not cause major alterations in ZDV pharmacokinetics, and routine dosage adjustment is not warranted when these two drugs are used in combination.
Publication Types:
Keywords:
- AIDS Vaccines
- Acquired Immunodeficiency Syndrome
- Anti-HIV Agents
- HIV
- HIV Infections
- HIV Protease Inhibitors
- HIV Seropositivity
- Humans
- In Vitro
- Lamivudine
- Reverse Transcriptase Inhibitors
- Zidovudine
- pharmacokinetics
Other ID:
UI: 102213717
From Meeting Abstracts